New York Times highlights McClellan's leadership at FDA

Under the leadership of commissioner Mark B. McClellan, currently on leave as a core faculty member of CHP/PCOR, the U.S. Food and Drug Administration has taken some bold steps that have surprised observers, who expected the agency to avoid controversial issues and make pro-business decisions. This New York Times article discusses McClellan?s approach at the FDA and examines some recent agency decisions, such as banning ephedra and allowing over-the-counter sales of emergency birth control. The article includes comment from CHP/PCOR director Alan M. Garber. Read more »